/term/cyclically-adjusted-pb-ratio/STU:0C8 Catalent (STU:0C8) Cyclically Adjusted PB Ratio
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (STU:0C8) » Definitions » Cyclically Adjusted PB Ratio

Catalent (STU:0C8) Cyclically Adjusted PB Ratio : 3.62 (As of Jun. 20, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Catalent Cyclically Adjusted PB Ratio?

As of today (2024-06-20), Catalent's current share price is €50.87. Catalent's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €14.05. Catalent's Cyclically Adjusted PB Ratio for today is 3.62.

The historical rank and industry rank for Catalent's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:0C8' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.42   Med: 3.97   Max: 14.27
Current: 3.6

During the past years, Catalent's highest Cyclically Adjusted PB Ratio was 14.27. The lowest was 2.42. And the median was 3.97.

STU:0C8's Cyclically Adjusted PB Ratio is ranked worse than
73.57% of 753 companies
in the Drug Manufacturers industry
Industry Median: 1.85 vs STU:0C8: 3.60

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Catalent's adjusted book value per share data for the three months ended in Mar. 2024 was €18.363. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €14.05 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Catalent Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Catalent's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Cyclically Adjusted PB Ratio Chart

Catalent Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 9.91 3.31

Catalent Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.38 3.31 3.29 3.11 3.69

Competitive Comparison of Catalent's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Catalent's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalent's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Catalent's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Catalent's Cyclically Adjusted PB Ratio falls into.



Catalent Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Catalent's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=50.87/14.05
=3.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalent's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Catalent's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=18.363/131.7762*131.7762
=18.363

Current CPI (Mar. 2024) = 131.7762.

Catalent Quarterly Data

Book Value per Share CPI Adj_Book
201406 -2.329 100.560 -3.052
201409 3.159 100.428 4.145
201412 3.231 99.070 4.298
201503 3.483 99.621 4.607
201506 4.544 100.684 5.947
201509 4.273 100.392 5.609
201512 4.478 99.792 5.913
201603 4.343 100.470 5.696
201606 4.538 101.688 5.881
201609 4.389 101.861 5.678
201612 4.468 101.863 5.780
201703 4.810 102.862 6.162
201706 5.149 103.349 6.565
201709 6.561 104.136 8.302
201712 6.373 104.011 8.074
201803 6.497 105.290 8.131
201806 6.972 106.317 8.642
201809 9.026 106.507 11.167
201812 9.434 105.998 11.728
201903 9.844 107.251 12.095
201906 10.214 108.070 12.455
201909 10.243 108.329 12.460
201912 10.564 108.420 12.840
202003 12.782 108.902 15.467
202006 15.813 108.767 19.158
202009 15.846 109.815 19.015
202012 16.699 109.897 20.024
202103 18.315 111.754 21.596
202106 19.058 114.631 21.908
202109 19.987 115.734 22.757
202112 22.155 117.630 24.819
202203 23.496 121.301 25.525
202206 25.235 125.017 26.599
202209 26.372 125.227 27.751
202212 25.761 125.222 27.109
202303 24.403 127.348 25.252
202306 23.608 128.729 24.167
202309 19.884 129.860 20.177
202312 18.714 129.419 19.055
202403 18.363 131.776 18.363

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Catalent  (STU:0C8) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Catalent Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Catalent's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalent (STU:0C8) Business Description

Industry
Traded in Other Exchanges
Address
14 Schoolhouse Road, Somerset, NJ, USA, 08873
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Catalent (STU:0C8) Headlines

No Headlines